Loading
A phase 2 trial of Pucotenlimab in head and neck squamous cell carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07586124 by Lepu Biopharma Co., Ltd., with 80 participants planned, started 2026-07-06 and due to reach its primary completion in 2027-12. Interventions recorded: Becotatug Vedotin for Injection, Placebo, Pucotenlimab Injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lepu Biopharma, Pucotenlimab.
Shares Lepu Biopharma, Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Lepu Biopharma, Head and neck squamous cell carcinoma.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Shares Pucotenlimab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/